Abstracts tagged "remission and rheumatoid arthritis"

Abstract Number: 1933 • 2018 ACR/ARHP Annual Meeting
Histological Features and Tissue-Macrophage Phenotype of Synovial Biopsies Identify RA Patients in Sustained Remission at Risk of Disease Flare after Treatment Tapering or Discontinuation
Stefano Alivernini¹, Barbara Tolusso¹, Aziza Elmesmari², Laura Bui³, Giusy Peluso¹, Maria Rita Gigante¹, Samuel Finlay^2,4, Luca Petricca¹, Clara Di Mario¹, Simone Perniola^1,5, Anna Laura Fedele¹, Francesco Federico³, Iain B. McInnes^2,4, Gianfranco Ferraccioli¹, Mariola Kurowska-Stolarska^2,6 and Elisa Gremese¹, ¹Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS - Catholic University of the Sacred Heart, Rome, Italy, ²Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Institute of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS - Catholic University of the Sacred Heart, Rome, Italy, ⁴Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), Glasgow, United Kingdom, ⁵Department of Verona - University of Verona (ITALY), Verona, Italy, ⁶Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), Rome, Italy
Background/Purpose: Flares of immune-mediated inflammatory diseases, as Rheumatoid Arthritis (RA) occur unpredictably representing a major burden for patients and clinicians. We aimed to dissect the…
Abstract Number: 649 • 2016 ACR/ARHP Annual Meeting
Clinical Evaluation Usefulness of Standardized Protocol Strategies of Dose Reduction in Patients with Rheumatoid Arthritis in Clinical Remission Treated with Biologic Therapies. the Optibio Study
Carmen Bejerano¹, Natividad Oreiro¹, Carlos Fernandez-Lopez², Jose A Pinto-Tasende¹, Antonio Atanes¹, Bruno De Aspe¹, Genaro Graña Gil¹, Mercedes Freire¹, Manuel Acasuso³, Sonia Pertega⁴, Francisco J. de Toro¹ and Francisco J Blanco¹, ¹Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ²Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain, ³Centro de Salud San Jose, XAP Coruna, A Coruna, Spain, ⁴Epidemiology Unit, INIBIC - Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
Background/Purpose: The OPTIBIO study is a clinical trial whose primary endpoint is to evaluate the proportion of patients that after one year are maintained in…
Abstract Number: 2427 • 2014 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Katsutoshi Hiramatsu⁶, Aki Kuroki⁵ and Tsutomu Takeuchi⁷, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie, Tokyo, Japan, ⁶Medical, Abbvie, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Although available data has suggested successful withdrawal of a monoclonal antibody TNF blocker after achieving low disease activity (LDA) or remission over the short-term…
Abstract Number: 2408 • 2014 ACR/ARHP Annual Meeting
Frequency of Rheumatoid Arthritis Flares in Clinical Practice: Analysis of a Monocentric Cohort of Patients in Stable Remission or Low Disease Activity
Francesca Ometto¹, Costantino Botsios², Livio Bernardi¹, Bernd Raffeiner^2,3, Leonardo Punzi⁴ and Andrea Doria⁴, ¹Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ³Department of Medicine, Rheumatology - General Hospital Bolzano, Bolzano, Italy, ⁴Department of Medicine - DIMED, University of Padova, Padova, Italy
Background/Purpose Rheumatoid arthritis (RA) flares are predictive of structural damage even in case of stable disease course. No definition for flare has been validated to…
Abstract Number: 465 • 2013 ACR/ARHP Annual Meeting
Higher Titer Of Anti-Citrullinated Protein Antibodies In Biologic-Naïve Rheumatoid Arthritis Patients Are Candidate Biomarkers To Predict Sensitivity Leading To Clinical Remission With Abatacept; Data From The Abroad Study
Takao Fujii¹, Masahiro Sekiguchi², Kiyoshi Matsui², Masayasu Kitano², Motomu Hashimoto³, Koichiro Ohmura⁴, Aihiro Yamamoto⁵, Hideko Nakahara⁶, Keiji Maeda⁷, Akira Yokota⁸, Kenji Miki⁹, Naoki Shimmyo¹⁰, Takanori Kuroiwa¹¹, Kosaku Murakami¹², Yoshio Ozaki¹³, Kenshi Higami¹⁴, Ichiro Yoshii¹⁵, Yuji Nozaki¹⁶, Takashi Ikawa¹⁷, Satoshi Morita¹⁸, Yutaka Kawahito⁵, Norihiro Nishimoto¹⁹, Tsuneyo Mimori⁴ and Hajime Sano², ¹Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, ³The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ⁶Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁷Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁸Yokota Clinic for Rheumatology, Osaka, Japan, ⁹Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ¹⁰Kashiba Asahigaoka Hospital, Kashiba, Japan, ¹¹Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ¹²Dept of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹³Kansai Medical University Hirakata Hospital, Hirakata, Japan, ¹⁴Department of Rheumatology, Higami Hospital, Nara, Japan, ¹⁵Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹⁶Kinki University Faculty of Medicine, Sayama, Japan, ¹⁷Osaka Rehabilitation Hospital, Hannan, Japan, ¹⁸Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁹Osaka Rheumatology Clinic, Osaka, Japan
Background/Purpose: Biomarkers to predict each rheumatoid arthritis (RA) patient’s sensitivity for biologic disease modifying anti-rheumatic diseases, especially for the only T cell modulator abatacept (ABT),…
Abstract Number: 1275 • 2012 ACR/ARHP Annual Meeting
Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week 12
Bernd Raffeiner¹, Costantino Botsios², Francesca Ometto², Mariagrazia Canova², Livio Bernardi², Cristiana Vezzari², Silvano Todesco², Paolo Sfriso² and Leonardo Punzi², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy
Background/Purpose: Achievement of clinical remission not only early in disease course but also early in treatment course may be critical for functional outcome of patients…
Abstract Number: 773 • 2012 ACR/ARHP Annual Meeting
Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
Josef S. Smolen¹, D. Aletaha², D. Gruben³, J. D. Bradley⁴, S. H. Zwillich³, S. Krishnaswami³, B. Benda⁵ and C. Mebus⁶, ¹Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Pfizer Inc., Groton, CT, ⁴Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ⁵Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This analysis evaluated the rates…
Abstract Number: 771 • 2012 ACR/ARHP Annual Meeting
Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results
Yoshiya Tanaka¹, Shintaro Hirata¹, Shunsuke Fukuyo¹, Masao Nawata², Satoshi Kubo², Kunihiro Yamaoka² and Kazuyoshi Saito¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Discontinuing anti-TNF therapy after achieving a stable low disease activity (LDA) or remission (REM) state in rheumatoid arthritis (RA) has become an important area…
Abstract Number: 360 • 2012 ACR/ARHP Annual Meeting
Initial Introduction of Treat-to-Target Strategy in Patients with Recent Onset Rheumatoid Arthritis Is More Effective Than Delayed Introduction of Strategy with More Clinical and Functional Remission Achieved for 2-Years: Results of the Treating to Twine Targets (T-4) Study
Yukitomo Urata¹, Yoshihide Nakamura² and Ken-ichi Furukawa³, ¹Rheumatology, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ²Orthopaedic Surgery, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ³Pharmacology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Background/Purpose: To compare the clinical, radiological and functional efficacy of initial versus delayed introduction of strategy which is treat-to-target to patients with recent onset rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].